Last reviewed · How we verify
Moderate-dose Dexmedetomidine
At a glance
| Generic name | Moderate-dose Dexmedetomidine |
|---|---|
| Also known as | Yisi |
| Sponsor | Tang-Du Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department (PHASE4)
- Effect of Dexmedetomidine on Tear Production in Angioplasty Patients (NA)
- Comparative Dose-Response of Intrathecal Dexmedetomidine for Post-Spinal Shivering (PHASE3)
- Intravenous Sedation and Analgesia Versus Local Anesthesia During Microwave Ablation of Benign Thyroid Nodules (NA)
- Impact of Frailty on Nalbuphine Dose for Postoperative Analgesia in Elderly Patients Undergoing Laparoscopic GI Surgery
- Dexmedetomidine Versus Ketofol for Moderate Sedation in Endoscopic Retrograde Cholangiopancreatography (PHASE4)
- A Low Dose Dexmedetomidine in Sedation Colonoscopy (NA)
- Safety and Efficacy of Dexmedetomidine in Painless Colonoscopy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moderate-dose Dexmedetomidine CI brief — competitive landscape report
- Moderate-dose Dexmedetomidine updates RSS · CI watch RSS
- Tang-Du Hospital portfolio CI